In this study, both CTLA4 immune blockage alone and combination with CD44-targeted PIT increased the T cell infiltration into MOC1 tumor seven days after the treatments, suggesting that primary immune activation was augmented by CTLA4 immune blockade. Here, CTLA4 is linked to neoplasm.